Key facts
- NexEos Bio’s last known valuation is $36.7M (Feb 2026).
- It has raised $25.7M; the latest was Seed Round ($3.0M) in Feb 2026.
- Notable investors include National Institutes of Health, Altitude Lab, Golden Seeds, Golden Seeds Ventures, University of Utah.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for NexEos Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for NexEos Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NexEos Bio
Developer of therapeutic and diagnostic technologies designed to identify and treat eosinophil and cationic protein-mediated inflammation. The company's technology offers a topical ophthalmic therapy targeting cationic granule proteins in eosinophil-driven ocular diseases and a non-invasive imaging agent for detecting and monitoring eosinophilic esophagitis, enabling patients with inflammatory conditions and healthcare providers to improve disease detection, management, and treatment outcomes.
- Sector
- Healthcare
- HQ
- Pottstown, PA, United States
- Founded
- 2019
- Website
- nexeosbio.com/
- Ownership
- Privately Held (backing)
NexEos Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NexEos Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NexEos Bio in its N-PORT filings yet. We sweep new filings monthly.